About

OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. pH variability is a proven, simple and effective identifier of diseased tissue and provides a foundation for the development of a broad range of highly targeted therapeutics and imaging agents. OncoNano is the first company to advance product candidates using pH as a biomarker for cancer immunotherapy, therapeutic use and intra-operative imaging based on its pH-sensitive micelle technology.

pH is an indicator for several diseases including cancer, Alzheimer’s and metabolic disorders. By targeting pH, a clear delineation between diseased and healthy tissue can be digitalized to develop a broad range of targeted applications. OncoNano's platform is an ultra-pH-sensitive drug delivery vehicle (micelle) that has a digital ON-OFF response to pH changes: it switches ON in the more acidic environment of cells and stays OFF in normal cells. Conjugating these micelles with fluorescent probes provides sharp diagnostic or intraoperative tumor imaging at low doses. At high doses, the same micelles serve to alter the metabolism pathways and buffer the lysosomal pH in cancer cells, providing therapeutic benefit.

Board of Directors

Al Guillem, Ph.D.
Chairman of the Board, Former President of ZS Pharma, Inc.

Ravi Srinivasan, Ph.D.
Founder, President and CEO of OncoNano Medicine

John Dyett
Founder and Managing Director of Salem Partners, LLC

Paritosh Dhawale, Ph.D.
General Manager of Contrast Media at GE Healthcare

Joydeep Goswami, Ph.D.
President, Clinical NGS and Oncology at Thermo Fisher Scientific

PRESS RELEASES

July 2019 – OncoNano Closes Additional $23.7 Million in Second Tranche of Series A Financing, Bringing Total Series A Raise to $35.4 Million

May 2019 – OncoNano to Present Poster on First-in-Human Study of pH-Activated Platform for Detection of Solid Tumors During Surgery at 2019 ASCO Annual Meeting

January 2019 – OncoNano Receives Authorization to Proceed from FDA for IND Application and Fast Track Designation for ONM-100, Intraoperative Imaging Agent to Detect Tumors and Metastatic Lymph Nodes That Often Go Undetected During Surgery

December 2018 – OncoNano Announces Completion of Phase 1a Study and Expands into Phase 1b for Intraoperative Imaging Agent to Detect Tumors and Metastatic Lymph Nodes That Often Go Undetected During Surgery

July 2018 – OncoNano Announces Dosing of Patients in Phase 1 Clinical Trial with ONM-100, an Intraoperative Imaging Agent that Targets Tumor Acidosis for the Detection of Solid Tumors

May 2018 – OncoNano Announces $11.7 Million Series A Financing to Support Development of pH-activated Compound Platform for Disease Detection and Treatment

Publications

May 31, 2019 – ASCO 2019 Annual Meeting
Image Guided Surgery for Tumor Agnostic Detection of Solid Tumors Using the pH Activated Micellar Imaging Agent ONM-100

April 2017 – Advanced Drug Delivery Reviews
Investigation of endosome and lysosome biology by ultra pH-sensitive nanoprobes

December 2016 – Nature Biomedical Engineering
A transistor-like pH nanoprobe for tumour detection and image-guided surgery

November 2016 – Advanced Materials
Digitization of endocytic pH by hybrid ultra-pH-sensitive nanoprobes at single-organelle resolution

October 2016 – Nature Communications
Molecular basis of cooperativity in pH-triggered supramolecular self-assembly